Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.62 - $2.04 $36,422 - $45,865
-22,483 Reduced 12.83%
152,768 $268,000
Q1 2024

May 15, 2024

BUY
$1.66 - $2.42 $240,296 - $350,311
144,757 Added 474.71%
175,251 $331,000
Q4 2023

Feb 14, 2024

SELL
$1.25 - $2.35 $75,631 - $142,186
-60,505 Reduced 66.49%
30,494 $65,000
Q3 2023

Nov 14, 2023

BUY
$1.5 - $3.07 $136,498 - $279,366
90,999 New
90,999 $147,000
Q1 2023

May 15, 2023

SELL
$2.65 - $3.81 $758,970 - $1.09 Million
-286,404 Reduced 56.5%
220,469 $654,000
Q4 2022

Feb 14, 2023

BUY
$3.38 - $4.22 $327,697 - $409,137
96,952 Added 23.65%
506,873 $1.85 Million
Q3 2022

Nov 14, 2022

BUY
$3.43 - $5.83 $1.03 Million - $1.74 Million
298,973 Added 269.47%
409,921 $1.48 Million
Q2 2022

Aug 15, 2022

BUY
$4.41 - $5.69 $489,280 - $631,294
110,948 New
110,948 $587,000
Q3 2021

Nov 15, 2021

SELL
$4.79 - $6.68 $440,838 - $614,780
-92,033 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$5.35 - $6.35 $7,543 - $8,953
-1,410 Reduced 1.51%
92,033 $543,000
Q1 2021

May 17, 2021

SELL
$5.68 - $7.87 $11,360 - $15,740
-2,000 Reduced 2.1%
93,443 $562,000
Q4 2020

Feb 12, 2021

BUY
$5.25 - $8.56 $32,476 - $52,952
6,186 Added 6.93%
95,443 $660,000
Q3 2020

Nov 16, 2020

SELL
$5.78 - $7.47 $15,686 - $20,273
-2,714 Reduced 2.95%
89,257 $559,000
Q2 2020

Aug 14, 2020

BUY
$4.5 - $7.02 $413,869 - $645,636
91,971 New
91,971 $607,000
Q2 2019

Aug 14, 2019

SELL
$4.51 - $6.6 $5.09 Million - $7.44 Million
-1,127,934 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$5.16 - $6.85 $230,827 - $306,427
44,734 Added 4.13%
1,127,934 $7.03 Million
Q4 2018

Feb 14, 2019

BUY
$4.89 - $7.16 $5.3 Million - $7.76 Million
1,083,200 New
1,083,200 $5.49 Million

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $319M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.